Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
U.S. Government Accountability Office
Asia
Lilly-Innovent, Biogen-Eisai, FDA and more—Fierce Pharma Asia
FDA lambasts Lilly and Innovent's PD-1 application. Biogen and Eisai file formal comment against CMS. GAO suggests surprise FDA foreign inspections.
Angus Liu
Feb 11, 2022 6:22am
Gilead has sole rights to COVID-19 blockbuster Veklury: GAO
Apr 1, 2021 11:00am
GAO presses FDA to tackle its COVID inspection backlog
Mar 4, 2021 11:20am
Orphan drug market set to climb above $200B: report
Jun 22, 2017 10:33am
Limited domestic vaccine manufacturing endangers U.S. flu prep
May 16, 2017 3:54pm
Lawmakers pressure PTC on Emflaza price
Mar 23, 2017 9:08am
